D ecision analysis is a systematic evaluation of the underlying assumptions inherent in making choices. Clinicians and public health personnel spend much of their time evaluating situations that often require choosing between two or more alternatives-to operate or observe a client with abdominal pain; to spend money on education or treatment of the AIDS virus; to perform a myelogram or magnetic resonance imaging study on a cancer patient with back pain. Whether the choice is in the clinical or public health sector, the decision maker determines a course of action based on personal experience and knowledge gained from literature.
Decision analysis challenges one to clearly define goals, options, and underlying assumptions intrinsic to the decision making process to clarify the process and to reach more rational conclusions. Inability to obtain information critical to the analysis of a particular problem, or the revelation that one or more underlying assumptions are incorrect, may require additional information gathering and a subsequent change in the final decision.
Breast cancer is a cause of morbidity and mortality in women: mammography can reduce the mortality of breast cancer. A decision analysis approach to mammographic screening for breast cancer requires that the assumptions underlying the effectiveness of mammographic screening be analyzed, as well as the ultimate goals or outcomes associated with the institution of mammographic screening. The analysis of costs to an individ-ual or group compared with the benefits expected to that individual or group is cost-benefit analysis. Frequently, cost-benefit analysis is performed on a decision analysis model.
DECISION ANALYSIS

Identification of the Problem
Although possibly self-evident, the statement of the problem is often not identical when viewed from different perspectives. For example, a public health official may think of a flu epidemic in terms of numbers of hospital beds required during the epidemic, the cost to society in days lost from work, or the institution of a vaccination program. A nurse practitioner would be interested in a vaccination program but may be more concerned with diagnostic criteria and treatment strategies for clients who present with a flu-like illness. Finally, an individual client may be concerned with days of work lost, cost and side effects of vaccination or treatment, and threat to individual health.
The relative importance of vaccination, lost work days, treatment, cost of treatment, and hospital bed utilization is subject to an observer's perspective. The decision analysis model requires identification of the perspective at the outset, thereby clarifying the decision maker's biases and priorities. Using breast cancer as an example, one observer could define the problem as a subset of problems secondary to a diet high in fat consumption, while another might determine the problem to be the pain and suffering of women in the terminal stages of disseminated disease. A concise definition of the problem must precede the search for the solution to the problem.
Specification of the Target Group
Once a problem is clearly defined a target group must be specified. Selection of the target group involves determination of individuals at risk for the particular problem. Other factors (ie, degree of risk, an ability to effect change within a group, and cost) may also influence the selection of a particular group.
Breast cancer is a cause of morbidity and mortality in women: mammography can reduce the mortality.
For example, a substance may cause cancer when inhaled and is known to be present in the air in one particular room of a plant. When planning to reduce exposure to this substance by instituting a ventilation mask requirement, the group required to wear the mask would have to be specified. Proximity to the source of the substance may influence the exposure of persons working in the room where the substance is present; however, persons in rooms Sox, 1988.) Sensitivity, specificity, and predictive values are important parameters when considering screening tests. A useful tool to evaluate the importance of sensitivity and specificity during screening is a 2 X 2 table.
Consider a hypothetical screening test with a sensitivity and specificity of 90%, which will be applied to a population of 10,000 people, 100 of whom have the specified disease (see Table 1 ).
Referring to the table, 100 people have the condition. A sensitivity of 90% indicates that of those 100 people, 90% (or 90) will have a positive test; therefore, 90 people have true positive tests and 10 have false-negative tests. Of the 9,900 people who do not have the disease, 10% (or 990) will have a positive test result and be labeled falsepositives. The remaining 8,910 people would have true negative tests. Ninety people (8.3%) of 1,080 people who tested positive would actually have the disease.
Before the test it was known that 100 out of the 10,000 people had the disease, therefore the pretest probability of disease was 1%. By doing the test, a group has been selected with an 8.3% probability of disease, a tenfold improvement. However, if an additional test associated with considerable cost or risk to the individual must be done to confirm disease, or if there is no further test to indicate which of the 1,080 people actually have the condition, then the utility of the screening test may be questioned.
It is rare that a screening test will be both highly sensitive and specific. Mammography is considered a very sensitive test for breast cancer, but all women with a positive mammogram will not have breast cancer. A more specific confirmatory test, a biopsy, is often the next recommended test for a woman with a positive mammogram. The biopsy is a highly specific test capable of determining which women with a positive screening mammogram have a disease other than breast cancer, such as adenomatous breast disease.
To summarize, the utility of a screening test is influenced not only by the test characteristics, sensitivity, and specificity but also by the prevalence of the condition in the population and the consequences of obtaining a positive result.
Estimation of Program Costs
To calculate cost-benefit parameters, costs of a proposed program must be quantified not only in terms of financial costs but also in terms of morbidity and mortality of the screening procedure. For example, if the screening test is for stool occult blood, then the only real cost is of the testing and the inconvenience to those being tested. However, if the test is carotid angiography or exploratory laparotomy, then morbidity and mortality are expected as a result of the screening procedure in addition to the financial costs of the test.
Another consideration is costs that are not directly a result of a test, such as work time lost to participate in the screening test or costs secondary to additional tests necessitated by falsepositive results. Costs associated with the testing procedure are designated direct costs, and costs related to the screening test other than the actual testing are designated indirect costs.
The search for accurate cost estimates and hidden costs is often frustrated by a lack of verifiable information; therefore, a range of costs may be used to predict a range of final cost effectiveness. Inability to obtain reliable estimates of costs or other parameters required for the analytic model should not dissuade, but edu-100 9,900 10,000 10 8,910 8,920
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Selection of a Screening Test
Three important pieces of information must be estimated in choosing a test to screen a population for a disease. The sensitivity and specificity of the screening test must be approximated and the prevalence of the disease in the population must be estimated. Sensitivity refers to the percentage of people with the disease who will have a positive test. In other words, if a test has a sensitivity of 90%, then nine out of ten people who actually have the disease will have a positive test result. Specificity refers to the percentage of persons without the disease who will also have a negative test. For example, if a screening test with a specificitv of 90% is administered to 100 individuals who do not have the condition in question, then 90 of those people will have a negative test and 10 will have a false-positive test.
Sensitivity and specificity are useful tools when determining the utility of a screening test, but they must always be interpreted in terms of the prevalence of the disease in the population. Using Baye's Theorem, one mav derive the predictive value of a positive test (the likelihood of having the disease given a positive test) and the predictive value of a with a shared ventilation system also may be exposed.
An estimation of the exposure level that presents a health hazard and of the levels in different areas of the plant is important when considering which persons would be required to wear masks. In a decision analysis model, the estimate of risk of the target group(s) is of great importance when defining the group that may be tested or the object of an intervention strategy. 
Estimation of Program Benefits
As with program costs, the benefits of any program must be estimated if one is to compare costs with benefits. Benefits may be calculated as reduction in mortality, reduction in morbidity, reduction in years of productive life lost, enhancement in quality of life, financial savings, or days of work saved.
The number of lives saved is an obvious benefit of a screening program that detects a potentially fatal disease, only if the screening program detects individuals in a more treatable phase or in an identifiable preillness state. For example, routine Pap screening of asymptomatic females detects women with dysplasia of the cervical epithelium, which is not life-threatening but may progress to cancer. Treatment with local surgery can prevent the chance of progression. Similarly, Pap screening may detect cases of carcinoma in situ, a condition that is pre-invasive cancer and, if left untreated, will become invasive cancer and threaten the life of the individual.
Two assumptions underlie the application of screening tests to malignant diseases. First, the screening test should be able to detect those with the disease at an earlier stage than a group that is not tested. Second, treating the particular cancer in an earlier stage will lower overall mortality rates. Whereas the first assumption may be validated by comparing stage of disease in tested individuals with those in a non-screened control group, the second assumption may be affected by two potential biases: lead-time bias and length bias.
If a disease is detected two years earlier than if the individual were not screened but the lifespan of that person is not affected, then measurements such as five-vear survival will be artificiallv increa;ed bv the screening procedure. In actuality, the individual is living longer from time of diagnosis only because the diagnosis is made earlier by a screening test than it would have been otherwise.
This artificial lengthening of life by earlier detection of an eventually fatal condition is termed lead-time bias. All that has been accomplished by screening is lengthening the time between diagnosis and death.
Length bias refers to a tendency to diagnose more indolent cases of a disease with a screening program, thereby artifactually increasing stage specific survival. For example, if prostate biopsy were to be performed on a group of men over age 60, some of the biopsy specimens would contain foci of cancer. If the group of men with prostate cancer detected by screening were compared with a group of men with prostate cancer not diagnosed by screening, then the screened group may have a longer survival.
Men in the group diagnosed without screening may well include a greater proportion of men with symptoms of prostate cancer. The presence of symptoms may select a group of cancers that are biologically different from those cancers detected in asymptomatic men.
The presence of symptoms may well select a group of cancers that are biologically different from those detected in asymptomatic men. The symptomatic cancers may be more aggressive and faster growing than the cancers detected by screening and would therefore tend to have a lower five-year survival.
Both lead-time and length biases can be controlled by prospectively comparing mortality in populations that have been screened with mortality in populations that have not been screened (Winawer, 1985) .
Another issue that must be addressed concerning mortality is the risk of death associated with the screening test. No test is risk free, but most do not involve a risk of mortality. However, some tests, such as coronary angiography or liver biopsy, have a predictable mortality, albeit small, and any increased risk of mortality associated with a screening test must be included in the decision analysis model.
Mortality is an easily measured outcome and often is used to judge the absolute efficacy of an intervention. However, other measurements of effect may be of equal or greater value, such as years of productive life lost (YPLL). YPLL is a measure of years of life lost prior to a given age, often 65 years since it is frequently the age of retirement.
Using YPLL as an endpoint, curing illness in a 20-year-old is valued more than curing illness in a 70-yearold. For instance, the number one cause of mortality for males in the United States is cardiovascular disease, but the number one cause of YPLL is accidents. A decision analysis model that uses YPLL as the main benefit of a program would place more importance on curing a disease 10 a younger person.
Many other factors can be included in the discussion of benefits of a particular health program, especially when considered from a corporate point of view. These include reduction in number of work days lost, decrease in payment of disability benefits, and reduction in costs needed to train replacement employees.
Important benefits that are difficult to quantitate, and therefore less likely to be used in the decision analysis model, include reduction in discomfort and suffering through the prevention of disease or less intensive s,' = 0.70 27 x 0.70 = 18.9 cases diagnosed with local disease The stage of the cancer at the time of diagnosis is of extreme importance to survival. Breast cancer may be staged using the tumor, node, and metastasis (TNM) system. An advanced local tumor or axillary nodes positive for metastases indicate increased risk of metastatic disease in the future, and therefore decreased chance of survival. Metastatic breast cancer, or cancer that has spread outside of the breast and axillary lymph nodes, is treatable but usuallv not considered "curable." Although some women with disseminated breast cancer achieve prolonged remissions with hormonal therapy or chemotherapy, the majoritv do not.
Stage at diagnosis is clearly an important prognostic factor. Fiveyear survival rates for women diagnosed between 1977 and 1982 in the U.S. in stages I, II, III, and IV were 96%, 81%, 52%, and 16% respectively (Sondik, 1986) . The purpose of mammographic screening is to detect cancers in an earlier stage, thereby reducing mortality from the disease.
Mammography
Mammography is the only screening modality shown in prospective randomized trials to reduce mortality from a specific cancer. Clinical trials in the U. S., Sweden, and the Netherlands have demonstrated an approximately 30% reduction in breast cancer mortality among women aged 50 to 65 years who are offered mammography in addition to their regular health care (Shapiro, 1977; Tabar, 1985a,b; Verbeek, 1985a,b) . A smaller but significant reduction in mortality was demonstrated in the Health Insurance Plan trial in New York State for women aged 40 to 49 years. However, studies outside the U.S. have not confirmed the benefit of mammography in the 40 to 49 year age group, and the cost-benefit of screening in this population is debated (Eddy, 1988) .
The incidence of breast cancer steadily rises with age; thus, mammography will detect more cancers as the age of the population being screened increases. Detecting a
APPLICATION IN THE WORKPLACE
Although this method is extremely subjective, a decision maker who neglects to give credit for less quantifiable outcomes may exclude very important variables from the analytic model.
Breast Cancer Problem
Breast cancer is the most common non-skin cancer in women and is the second leading cause of cancer "death in women. In 1989, an estimated 142,000 women will be diagnosed with breast cancer. Based on past survival rates, more than one third of those will die of the cancer (Silverberg, 1989) . Risk factors for breast cancer include age, nulliparity, early onset of menstruation, late menopause, family history of breast cancer, late age of first childbirth, obesity, a high-fat diet, and certain types of benign breast disease.
The incidence of breast cancer increases with age, but the clinical course of the disease suggests that it is different in the premenopausal and postmenopausal woman. Premenopausal breast cancer cells are less likely to possess receptors for the hormones estrogen and progesterone. The presence of these receptors correlates with increased five-year survival. Even when controlling for stage at diagnosis and other prognostic factors, women with premenopausal cancer have poorer five-year survival rates than postmenopausal women. treatment for disease diagnosed in an earlier stage.
The benefits of a health intervention may range from improving an individual's sense of well-being to reducing costs of overall health care. Some of these potential benefits have been highlighted, but a complete list for any specific intervention is limited only by imagination and perspective.
Cost-Benefit Ratio
Another useful measure of a program's effectiveness is the cost-benefit ratio, especially if budgetary constraints dictate that some interventions will be funded and others will not. The cost-benefit ratio is simple, with the cost usually expressed in terms of currency. The denominator is chosen by the decision maker, eg, lives saved, YPLL, or work days missed. Work days missed and YPLL are expressed in different units (days versus years) but can be easily added or subtracted from each other by converting days to years, or vice versa.
Other outcomes, however, may not be combined as easily, and some authors have used a dimensionless quantity-quality points-to represent the denominator (Eddy, 1986) . Using the points strategy, the decision maker assigns points based on the relative merits of each of a program's benefits. For example, 100 points may be assigned to reduction in pain for a person with cancer, whereas a cure would be assigned 500 points and prevention of the cancer would be worth 1,000 points. 3.8 x $8,700 savings per client = $33,060 (Carter, 1987) . be $900 (Eddy, 1988) , then the costs of evaluating false-positive mammograms per year would be: 10,000 employees x .90 x .01 x $900 = $81,000.
The costs of lost labor due to appointments for screening, assuming an average of two hours off work for each mammogram and..an average hourly wage of $12, would be: 10,000 employees x .90 x 2 hours x $12 = $216,000. Total costs of the program would therefore be $1,017,000.
Potential financial benefits of mammographic screening include a reduction in costs of health care and disability payments achieved through less radical treatment of earlier stage tumors and decreased costs related to hiring and training of new employees. Furthermore, society would benefit from the continued productivity of women who are able to remain in the work force.
Labor contributed to society can be estimated by assuming that each employee who would die of breast cancer would die at approximately 60 years of age, reducing their effective employment by an average of five years. Assuming an average salary of $25,000, the loss of productivity can be calculated as follows: 1.9 (deaths averted) X $25,OOO/year x 5 years = 237,500.
Savings in treatment costs can be estimated by multiplying the number of women who would be diagnosed with local disease instead of advanced disease by the savings per tases (see Table 2 ).
Expected deaths by five years may be obtained by multiplying the number of cases in each stage by their respective expected mortality rates (see Table 3 ).
Screening will not change stage specific mortality if lead-time and length bias have a negligible effect, but it will increase the number of cases diagnosed in an SI' With free screening and a compliance rate of 90%, the percentage of cases diagnosed in stage I could be increased to 70% (see Tables 4 and 5) .
Reduction in 5-year mortality from screening is calculated by subtracting deaths with screening (10.7) from deaths without screening (12.6), which equals 1.9.
If the average case in the 50-to 65year age group occurs at age 58 and the average death occurs 2.5 years after diagnosis at age 60.5, then each death would result in 4.5 years of life lost prior to retirement age and 19.5 years of life lost prior to age 65.
Costs of the .program include the cost of mammography, labor, time lost due to screening, and costs of evaluating false-positive mammograms. If each mammogram costs $80 (Eddy, 1988) and 90% compliance is, achieved, then the total cost of the mammograms for one year would be: 10,000 employees x .90 x $80 = $720,000.
Estimating a 1% chance of a falsepositive mammogram and the cost of a work-up for a false mammogram to breast cancer in a 40-year-old may yield greater results in terms of YPLL, but many more screening exams must be done to detect one case in a group of 40-year-old women compared with a group of 55-year-old women. Therefore the cost of reducing YPLL is actually less in the older group than the younger group (Eddy, 1988) .
The age at which screening should begin varies with the group making the recommendation: the National Cancer Institute recommends screening beginning at age 50 (NIH, 1984) ; the American Cancer Society recommends beginning at age 35 (ACS, 1983) . The decision analysis model is a useful tool to help quantify the costs and benefits of screening different age groups of asymptomatic women.
APPLICATION OF THE DECISION MODEL TO MAMMOGRAPHY
An example of the decision analysis model will illustrate the utility of this analytic method for evaluating the costs and benefits of a mammographic screening program. The survival rates and stage information used in the example below are from a model developed for a class in cancer detection and prevention and are not generalizable to all settings. This particular method is based on a method described by Eddy (1986) .
Assume that a company proposes to provide yearly mammography free of charge to 10,000 female employees between the ages of 50 and 65 years. To conduct a cost-benefit analysis for the company, many parameters must be estimated, including the incidence of breast cancer for the group to be screened, the stage and survival before screening, the stage and survival for the group after screening, years of productive life gained by screening, the cost of mammography, and potential economic benefits to the company from screening.
Two stages will be used for the model: SI includes carcinoma in situ and lesions confined to the breast tissue; S2 includes tumors locally invasive of skin, muscle, or lymph nodes and tumors with distant metas- nography will reduce morbidity associated with more extensive treatment required for advanced cancers and will reduce cost of treatment, cost of replacement of employees, days absent from work, and disability payments. Finally, by detecting breast cancer at earlier and more treatable stages, the suffering of women with breast cancer can be substantially reduced. The example of decision analysis applied to mammographic screening serves as an introduction to the process of cost-benefit analysis. It is hoped that decision analysis and costbenefit modeling will help health planners as they design and institute mammography programs.
individual (see Table 6 ).
Savings derived from a reduction in training and hiring new employees can be estimated by multiplying the number of deaths prevented by the average cost of retraining a new employee, which will be estimated as being the cost of one year of average salary ($25,000). The full cost of hiring and retraining will not be saved since all employees retire eventually.
If the average worker is employed for 20 years, and preventing the death of an employee adds an average of five years to the employee's length of employment, then the cost of hiring and training a new employee can be avoided for an average of five years (see Table 7 ).
Total savings from labor saved, treatment costs, and hiring/retraining costs would therefore be $282,435.
The total costs of the mammography screening program can be computed by subtracting the savings from the cost of the program: $1,017,000 (total cost) -$282,435 (total savings) = $734,565.
A cost-benefit analysis of this simplified model could be expressed as cost per life saved, cost per year of life saved prior to retirement, and cost per year of life lost prior to age 80 (see Table 8 ).
Although the cost and benefits of business sponsored mammographic screening programs have not been analyzed in the literature, Carter (1987) reported on a mammography program in a Health Maintenance Organization in Washington state. Using a screening questionnaire to quantify an individual's risk of developing breast cancer, clients are screened yearly, every three years, every five years, or on referral according to their risk level. The cost of a mammogram is estimated to be $26.50.
The number of mammograms performed per year are approximately one fourth of those done if clients were mammogramed every other year from ages 40 to 49 and every year after age 50, as has been recommended by some U.S. groups.
Savings derived from a reduction in cost of treatment of earlier stages of breast cancer are greater than the costs of the mammography program, yielding a net monetary savings to the Health Maintenance Organization. A similar mammography program could be suggested by companies who utilize Health Maintenance Organizations as their primary health provider.
CONCLUSION
Decision analysis and cost effectiveness estimates allow one to evaluate costs and effects of mammographic screening applied to a particular population. An increase in mammographic screening will decrease mortality from breast cancer. In addition to saving lives, mam-1.
2.
3.
Mammography is considered a very sensitive test for breast cancer, but all women with a positive mammogram Will not have breast cancer.A more specific confirmatory test, a biopsy, is often the next recommended test for a woman with a positive mammogram.
The utility of a screening test is influenced not only by the test characteristics, sensitivity, and specificity, but also by the prevalence of the condition in the population and the consequences of obtaining a positive result.
Benefits may be calculated as reduction in mortality, reduction in morbidity, reduction in years of productive life lost, enhancement in quality of life, financial savings, or days of work saved.
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